Cough Plaster for post-infectious cough (pattern of wind-cold invading the lung): single-group case series study

注册号:

Registration number:

ITMCTR2025001155

最近更新日期:

Date of Last Refreshed on:

2025-06-12

注册时间:

Date of Registration:

2025-06-12

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

拔咳贴治疗感染后咳嗽(风寒恋肺证)无对照病例系列研究

Public title:

Cough Plaster for post-infectious cough (pattern of wind-cold invading the lung): single-group case series study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

拔咳贴治疗感染后咳嗽(风寒恋肺证)无对照病例系列研究

Scientific title:

Cough Plaster for post-infectious cough (pattern of wind-cold invading the lung): single-group case series study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张秉睿

研究负责人:

吴圣贤

Applicant:

Bingrui Zhang

Study leader:

Shengxian Wu

申请注册联系人电话:

Applicant telephone:

15708407581

研究负责人电话:

Study leader's telephone:

010-84015528

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2498575902@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wushx@sina.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号北京中医药大学

研究负责人通讯地址:

北京市东城区海运仓5号北京中医药大学东直门医院

Applicant address:

Beijing University of Chinese Medicine Beijing 100029 China

Study leader's address:

Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学东直门医院

Applicant's institution:

Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024DZMEC-544-02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学东直门医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/12/12 0:00:00

伦理委员会联系人:

韩雪婷

Contact Name of the ethic committee:

Xueting Han

伦理委员会联系地址:

北京市东城区海运仓胡同5号

Contact Address of the ethic committee:

Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-84012709

伦理委员会联系人邮箱:

Contact email of the ethic committee:

dzmyyec@126.com

研究实施负责(组长)单位:

北京中医药大学东直门医院

Primary sponsor:

Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

研究实施负责(组长)单位地址:

北京市东城区海运仓5号

Primary sponsor's address:

No. 5 Haiyun Cang Dongcheng District Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

东城区

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

具体地址:

北京市东城区海运仓胡同5号

Institution
hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Address:

Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

经费或物资来源:

自费

Source(s) of funding:

self-paying

研究疾病:

感染后咳嗽

研究疾病代码:

Target disease:

post-infectious cough

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

病例研究

Case study

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

初步探索拔咳贴对感染后咳嗽(风寒恋肺证)的有效性及安全性。

Objectives of Study:

To explore the effectiveness and safety of Cough Plaster for post-infectious cough (pattern of wind-cold invading the lung).

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合感染后咳嗽西医诊断标准; ②符合阳虚风寒恋肺证中医辨证标准; ③病程3~6周; ④签署知情同意书时,受试者年龄不限,男女不限; ⑤自愿受试并签署知情同意书。

Inclusion criteria

① Meet the diagnostic criteria for post-infectious cough; ② Meet the traditional Chinese medicine diagnostic criteria of pattern of wind-cold invading the lung; ③ Duration of the disease is 3~6 weeks; ④ No restrictions of gender and age; ⑤ Volunteer to be tested and sign the informed consent.

排除标准:

①下列疾病引起的咳嗽,如慢性支气管炎、支气管哮喘、支气管扩张、气管-支气管结核、咳嗽变异型哮喘、嗜酸粒细胞性支气管炎、鼻后滴流综合征、胃-食管反流性咳嗽、心理性咳嗽,以及百日咳; ②合并肺结核活动期、肺部感染、慢性阻塞性肺疾病或其他肺部疾病(如肺栓塞、间质性肺病等); ③合并有心血管系统疾病(包括但不限于:心律失常,如房颤、频发的房性早搏和室性早搏等) 、神经系统、血液及造血系统等重要器官和系统有严重原发性疾病,以及合并有精神疾患等而无法合作者; ④经规范治疗后收缩压≥160mmHg和/或舒张压≥100mmHg者,筛选时静息(至少10分钟)状态下测得; ⑤因口服ACEI类等药物出现刺激性干咳症状的患者; ⑥体温在 37.3℃及以上,或白细胞增高(大于 1.2 ULN); ⑦筛选期肝肾功能实验室检查结果异常:ALT、AST>1.5 ULN,Cr>ULN; ⑧妊娠或准备妊娠及哺乳期妇女; ⑨有严重胃肠疾患或经胃肠手术后经研究者判断可能影响药物吸收者; ⑩恶性肿瘤患者; ⑪过敏体质者,或对本试验用药品成分过敏者; ⑫筛选前3个月内过量(每周饮酒超过21单位,1单位=8g或10mL纯酒精)饮酒,且服药过程中无法停止饮酒者; ⑬服用试验用药品前72 小时内已使用过其他治疗本病的中、西药物或治疗(如穴位贴敷、针灸等)者; ⑭近1个月内参加了其他药物/器械临床试验的受试者; ⑮研究者判定依从性差或其他任何不适合参加本项试验的受试者。

Exclusion criteria:

① Cough caused by the following diseases such as chronic bronchitis bronchial asthma bronchiectasis tracheo-bronchial tuberculosis cough variant asthma eosinophilic bronchitis postnasal drip syndrome gastro-esophageal reflux cough psychogenic cough and pertussis; ② Combination of active tuberculosis lung infection chronic obstructive pulmonary disease or other lung diseases (e.g. pulmonary embolism interstitial lung disease etc.); ③ Combined cardiovascular system diseases (including but not limited to: cardiac arrhythmia such as atrial fibrillation frequent atrial premature beats and ventricular premature beats etc.) neurological blood and hematopoietic system and other important organs and systems with serious primary diseases as well as combined with psychiatric disorders etc. and can not cooperate; ④ Those with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg after standardized treatment measured in the resting (at least 10 minutes) state at screening; ⑤ Patients with symptoms of irritating dry cough due to oral administration of drugs such as ACEIs; ⑥ Temperature of 37.3°C and above or elevated leukocytes (> 1.2 ULN); ⑦ Abnormal results of laboratory tests of liver and renal function during the screening period: ALT AST > 1.5 ULN Cr > ULN; ⑧ Pregnant or preparing for pregnancy and lactating women; ⑨ Those with severe gastrointestinal disorders or those who have undergone gastrointestinal surgery that in the judgment of the investigator may interfere with drug absorption; ⑩Patients with malignant tumors; ⑪Persons with allergies or those who are allergic to the components of the drugs used in this test; ⑫ Those who have consumed alcohol in excess (more than 21 units of alcohol per week 1 unit = 8g or 10mL of pure alcohol) in the 3 months prior to screening and who are unable to stop consuming alcohol during the course of using the drug; ⑬ Those who have used other Chinese or Western medicines or treatments (e.g. acupressure acupuncture etc.) for the treatment of the disease within 72 hours before using the test drug; ⑭ Subjects who have participated in clinical trials of other drugs/devices in the last 1 month; ⑮ Subjects judged by the investigator to have poor adherence or any other inappropriate for participation in this trial.

研究实施时间:

Study execute time:

From 2024-12-13

To      2025-02-01

征募观察对象时间:

Recruiting time:

From 2024-12-13

To      2025-02-01

干预措施:

Interventions:

组别:

拔咳贴组

样本量:

60

Group:

Cough Plaster Group

Sample size:

干预措施:

拔咳贴1片/次,1次/日,贴天突穴,夜晚用

干预措施代码:

Intervention:

Cough Plaster 1 piece each time, once a day, applied to the Tian Tu acupoint, for use at night.

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Grade IIIA hospital

测量指标:

Outcomes:

指标中文名:

咳嗽消失时间

指标类型:

次要指标

Outcome:

Cough disappearance time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽NRS评分

指标类型:

次要指标

Outcome:

Cough numerical rating scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易咳嗽程度评分变化

指标类型:

次要指标

Outcome:

Cough Evaluation Test CET

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽生活质量测评(莱切斯特咳嗽问卷)

指标类型:

次要指标

Outcome:

Leicester Cough Questionnaire (LCQ)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

单项症状消失率

指标类型:

次要指标

Outcome:

Disappearance rate of single symptom

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候疗效

指标类型:

次要指标

Outcome:

Curative effect of TCM syndrome

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽消失率

指标类型:

主要指标

Outcome:

Cough disappearance rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命体征(体温、血压、呼吸、心率)

指标类型:

副作用指标

Outcome:

Vital signs

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

副作用指标

Outcome:

adverse reaction

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

结束

Completed

年龄范围:

最小 0
Min age years
最大 99
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF)

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above